Literature DB >> 2219254

The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance.

P M Ness1, R S Shirey, S K Thoman, S A Buck.   

Abstract

Delayed serologic transfusion reactions (DSTRs) and delayed hemolytic transfusion reactions (DHTRs) were studied in a large tertiary-care hospital. A DSTR was defined by the posttransfusion finding of a positive direct antiglobulin test (DAT) and a newly developed alloantibody specificity. A DHTR was defined as a DSTR case that showed clinical and/or laboratory evidence of hemolysis. Thirty-four cases of DSTR, 70 percent of which were due to anti-E and/or -Jka, were documented prospectively over a 20-month period. Retrospective review of the medical records found clinical evidence of hemolysis in only 6 (18%) of the 34. Thus, the incidence of DSTR was 1 (0.66%) of 151 recipients with posttransfusion samples available for testing, whereas the incidence of DHTR was only 1 (0.12%) of 854 patients tested. Fifteen of the 34 patients were followed for up to 174 days after reaction. Twelve of the 15 still demonstrated a positive DAT with anti-IgG only. Eluate studies indicated that the persistence of a positive DAT after DSTR or DHTR may involve several immunologic mechanisms, including the development of posttransfusion autoantibodies. This study indicates 1) that DSTRs are a frequent finding in multiply transfused patients, although most cases are benign and fail to meet rigid criteria for DHTR, and 2) that the persistence of a positive DAT after DSTR or DHTR is common.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219254     DOI: 10.1046/j.1537-2995.1990.30891020325.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  29 in total

1.  Hemolytic Transfusion Reactions.

Authors:  Erwin Strobel
Journal:  Transfus Med Hemother       Date:  2008-09-18       Impact factor: 3.747

2.  Presence of atypical antibody (anti Jk(a)) in a multi transfused transfusion dependent anemia patient.

Authors:  R S Mallhi; J Philip; T Chatterjee; U Dimri
Journal:  Med J Armed Forces India       Date:  2015-02-16

3.  Jk(a-b-) phenotype screening by the urea lysis test in Thai blood donors.

Authors:  Suparat Deelert; Pattrawan Thippayaboon; Wimolpak Sriwai; Pramote Sriwanitchrak; Jintana Tubrod; Pawinee Kupatawintu; Oytip Nathalang
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

4.  Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis.

Authors:  Eldad A Hod; Set A Sokol; James C Zimring; Steven L Spitalnik
Journal:  Int J Clin Exp Pathol       Date:  2008-05-30

Review 5.  Pathogenesis and mechanisms of antibody-mediated hemolysis.

Authors:  Willy A Flegel
Journal:  Transfusion       Date:  2015-07       Impact factor: 3.157

6.  Delayed Serological Transfusion Reaction After Platelet Transfusion Due to Anti-e.

Authors:  Deepti Sachan; Aswin Kumar; Dinesh Jothimani; Mohamed Rela
Journal:  Indian J Hematol Blood Transfus       Date:  2016-01-19       Impact factor: 0.900

7.  Kidd Blood Group Genotyping for Thalassemia Patient in Iran.

Authors:  Seyedeh Farzaneh Jalali; Arezoo Oodi; Azita Azarkeivan; Samira Gudarzi; Naser Amirizadeh
Journal:  Indian J Hematol Blood Transfus       Date:  2020-04-29       Impact factor: 0.900

8.  Delayed hemolytic transfusion reaction in a thalassemic child.

Authors:  R Kashyap; V P Choudhry
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

9.  An unexpected development after surgery-post-transfusion purpura!

Authors:  Gavin Falk; Charles G Winans; Krista Bowens; Daniel W Bougie; Brian R Curtis; Richard H Aster
Journal:  Am J Hematol       Date:  2016-06-03       Impact factor: 10.047

10.  Facts and Fallacies of Kidd Antibodies: Experience in a Tertiary Care Hospital in North India.

Authors:  R N Makroo; Sweta Nayak; Mohit Chowdhry; Prashant Karna
Journal:  Indian J Hematol Blood Transfus       Date:  2016-05-04       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.